Valneva SE
World Trade Center Lyon, Tour Oxygène
10-12 boulevard Marius Vivier Merle
Lyon
69003
France
Tel: 33-4-78-76-61-01
Website: http://www.valneva.com/
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.LEADERSHIP:
CEO: Thomas Lingelbach
CFO: Reinhard Kandera
144 articles about Valneva SE
-
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
3/26/2024
Valneva SE, a specialty vaccine company, announced the initiation of a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus.
-
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
3/20/2024
Valneva SE reported its consolidated financial results for the year ending December 31, 2023 and provided several key corporate updates.
-
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
2/29/2024
Valneva SE, a specialty vaccine company, announces that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus.
-
On Wednesday, the CDC’s Advisory Committee on Immunization Practices voted to recommend Valneva’s chikungunya virus vaccine Ixchiq for certain high-risk patient groups.
-
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
2/15/2024
Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2023 and provided first full year 2024 sales and R&D expense guidance.
-
The French vaccine maker on Monday said it sold a priority review voucher, which was awarded by the FDA in November 2023 alongside an approval for its chikungunya vaccine, to an undisclosed buyer.
-
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
1/10/2024
Valneva SE announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.
-
Valneva Provides Updated 2023 Financial Guidance
12/29/2023
Valneva SE, a specialty vaccine company, announced that the Company is modifying its financial guidance for 2023.
-
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
12/20/2023
Saint-Herblain, December 20, 2023 – Valneva SE, a specialty vaccine company, announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting held on December 20, 2023.
-
Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin®
11/22/2023
Albumedix Ltd announces that Recombumin® is critical to the manufacture of the first FDA- licensed chikungunya vaccine.
-
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
11/15/2023
Valneva SE announced the availability of documentation for its Extraordinary General Meeting which will be held on December 20, 2023 at 2:00 p.m. CET at the Radisson Blu Hotel, 6 place Aristide Briand, 44000 Nantes, France.
-
Following a more than two-month delay to its PDUFA action date, Valneva’s chikungunya vaccine Ixchiq has won the regulatory race beating biotech Bavarian Nordic.
-
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
11/9/2023
Valneva SE, a specialty vaccine company, reported consolidated financial results for the first nine months of the year, ended September 30, 2023.
-
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
10/25/2023
Valneva SE announces the submission of a marketing application with the European Medicines Agency for approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553.
-
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
10/11/2023
Valneva SE, a specialty vaccine company, announces it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.
-
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
9/21/2023
Valneva SE, a specialty vaccine company, reported its consolidated financial results for the first half of the year, ended June 30, 2023.
-
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
9/7/2023
Valneva SE and Pfizer Inc. announced positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given as a booster.
-
Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review
8/29/2023
Valneva SE announced that Health Canada has completed screening validation of the Company’s regulatory application for marketing approval of its single-shot chikungunya vaccine candidate VLA1553 in persons aged 18 years and above, and has determined that the New Drug Submission application is sufficiently complete to permit a substantive review.
-
Valneva Announces Extension of Existing Loan Agreement
8/17/2023
Valneva SE, a specialty vaccine company, announced an agreement to increase the principal amount of its existing $100 million senior secured debt financing agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed.
-
Valneva’s chikungunya vaccine candidate will have to wait three more months for a decision from the regulator, potentially giving rival Bavarian Nordic additional time to catch up.